Business
BioDlink Completes First International Shipment of Bevacizumab to Colombia
BioDlink announced the first international shipment of its bevacizumab injection biosimilar to Colombia in partnership with Kexing BioPharm. Both companies marked this milestone with a special ceremony when specially-decorated transport vehicles arrived.
About this update from Kexing Biopharm Co., Ltd. Class A
[{"type":"list","items":[{"val":[{"type":"text","content":"Bevacizumab is a targeted therapy used to treat lung and colorectal cancers, both among the top three cancers ranked by death in Colombia [1] .","length":143,"tagName":"p"}]},{"val":[{"type":"text","content":"This inaugural shipment— dispatched around two months after Colombia's marketing approval — demonstrates the company's efficiency, while validating its antibody commercialization platform, as well as robust production quality and supply chain management systems.","length":273,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":416,"olType":false},{"type":"text","content":"SUZHOU, China, Oct. 27, 2025 /PRNewswire/ -- BioDlink announced the first international shipment of its bevacizumab injection biosimilar to Colombia in partnership with Kexing BioPharm. Both companies marked this milestone with a special ceremony when specially-decorated transport vehicles arrived.","length":299,"tagName":"p"},{"type":"image","alt":"logo (PRNewsfoto/BioDlink Biopharm Co., Ltd.)","displaySize":"","headline":null,"caption":"logo (PRNewsfoto/BioDlink Biopharm Co., Ltd.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":82,"url":"https://media.zenfs.com/en/prnewswire.com/40591ea8ba443c2f8ddacfe8dc9169da"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/bfhnGYVbJOyrwWPdCvLAIg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE0NTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/40591ea8ba443c2f8ddacfe8dc9169da","width":400,"height":82}},"href":"https://mma.prnewswire.com/media/2682341/BioDlink_EN_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor (VEGF), is widely used in the treatment of various cancers, including metastatic colorectal cancer (mCRC) and metastatic or recurrent non-squamous non-small cell lung cancer (nsNSCLC). According to industry estimates, bevacizumab injection achieved global sales of USD 8.5 billion in 2023[2].","length":377,"tagName":"p"},{"type":"text","content":"In July 2025, the company announced that its bevacizumab injection has received marketing approval from Colombia's National Institute for Surveillance of Medicines and Foods (INVIMA). This inaugural shipment—dispatched around two months after marketing approval—demonstrates...